Upload
thiery
View
23
Download
2
Tags:
Embed Size (px)
DESCRIPTION
Seminar in Palliative Care. September 26 – October 02, 2010 Salzburg, Austria in Collaboration with. The. EPEC-O. TM. Education in Palliative and End-of-life Care - Oncology. Project. - PowerPoint PPT Presentation
Citation preview
Seminar in Palliative CareSeptember 26 – October 02, 2010
Salzburg, Austria
in Collaboration with
The EPEC-O Curriculum is produced by the EPECTM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong Foundation.
Education in Palliative and End-of-life Care - Oncology
The
ProjectEPEC-O
TM
Nausea / Nausea / VomitingVomiting
Jamie H. Von Roenn, Jamie H. Von Roenn, MDMD
Northwestern University,Northwestern University,Feinberg School of Medicine, Feinberg School of Medicine,
Chicago, Illinois, USAChicago, Illinois, USA
Nausea / vomiting . . .Nausea / vomiting . . .
• DefinitionDefinition
Nausea is an unpleasant subjective Nausea is an unpleasant subjective sensation of being about to vomitsensation of being about to vomit
Vomiting is the reflex expulsion of gastric Vomiting is the reflex expulsion of gastric contents through the mouthcontents through the mouth
. . . Nausea / vomiting. . . Nausea / vomiting
• Impact very distressing:Impact very distressing:
Awareness of nauseaAwareness of nausea
Inability to keep food or fluids downInability to keep food or fluids down
Acid and bitter tastesAcid and bitter tastes
Unpleasant smells of vomitusUnpleasant smells of vomitus
Key pointsKey points
1.1. PathophysiologyPathophysiology
2.2. AssessmentAssessment
3.3. ManagementManagement
PathophysiologyPathophysiology
• Nausea Nausea
Subjective sensation (easily learned)Subjective sensation (easily learned)
Stimulation Stimulation
Gastrointestinal lining, CTZ, vestibular Gastrointestinal lining, CTZ, vestibular apparatus, cerebral cortexapparatus, cerebral cortex
• VomitingVomiting
Neuromuscular reflexNeuromuscular reflex
PathophysiologyPathophysiology
CortexCortexCortexCortex
Vestibular Vestibular apparatusapparatusVestibular Vestibular apparatusapparatus
GI tractGI tractGI tractGI tract
ChemoreceptorChemoreceptorTrigger Zone (CTZ)Trigger Zone (CTZ)
ChemoreceptorChemoreceptorTrigger Zone (CTZ)Trigger Zone (CTZ)
NeurotransmittersNeurotransmitters AcetylcholineAcetylcholine DopamineDopamine HistamineHistamine Neurokinin Neurokinin SerotoninSerotonin
NeurotransmittersNeurotransmitters AcetylcholineAcetylcholine DopamineDopamine HistamineHistamine Neurokinin Neurokinin SerotoninSerotonin
Vomiting centerVomiting center
CausesCauses
MMetastasesetastases
MMeningeal irritationeningeal irritation
MMovementovement
MMental anxietyental anxiety
MMedicationsedications
MMucosal irritationucosal irritation
MMechanical echanical
obstructionobstruction
MMotilityotility
MMetabolicetabolic
MMicrobesicrobes
MMyocardialyocardial
AssessmentAssessment• WhenWhen• Acute versus chronicAcute versus chronic• Intermittent or constantIntermittent or constant• Associated with sights or smellsAssociated with sights or smells• Eating patternsEating patterns• Bowel patternsBowel patterns• MedicationsMedications
ManagementManagement
• Dopamine Dopamine
antagonistsantagonists
• AntihistaminesAntihistamines
• AnticholinergicsAnticholinergics
• Serotonin Serotonin
antagonistsantagonists
• Neurokinin Neurokinin
antagonistsantagonists
• Prokinetic Prokinetic
agentsagents
• AntacidsAntacids
• Cytoprotective Cytoprotective
agentsagents
• Other Other
medicationsmedications
Gralla R, et al. J Clin Oncol, 1999.
Chemotherapy nauseaChemotherapy nausea
• AcuteAcute
< 24 hr< 24 hr
Chemoreceptor trigger zoneChemoreceptor trigger zone
Serotonin release in the gutSerotonin release in the gut
• DelayedDelayed
24 hr (may be days)24 hr (may be days)
Unclear mechanismUnclear mechanism
Chemotherapy Chemotherapy emetogenicityemetogenicity
Emetogenic Emetogenic ClassClass
Incidence acute Incidence acute vomitingvomiting
II Minimal < 10 %Minimal < 10 %
IIII Low 10 – 30 %Low 10 – 30 %
IIIIII Mild 30 – 60 %Mild 30 – 60 %
IVIV Moderate 80 – 90 %Moderate 80 – 90 %
VV High > 90 %High > 90 %
Dopamine antagonistsDopamine antagonists
• HaloperidolHaloperidol
• ProchlorperazineProchlorperazine
• Droperidol Droperidol
• ThiethylperazineThiethylperazine
• Promethazine Promethazine
• TrimethobenzamideTrimethobenzamide
• MetoclopramideMetoclopramide
• OlanzapineOlanzapine
• PerphenazinePerphenazine
Histamine antagonists Histamine antagonists (antihistamines)(antihistamines)
• DiphenhydramineDiphenhydramine
• MeclizineMeclizine
• HydroxyzineHydroxyzine
Acetylcholine antagonistsAcetylcholine antagonists(anticholinergics)(anticholinergics)
• ScopolamineScopolamine
Serotonin antagonistsSerotonin antagonists
• OndansetronOndansetron
• GranisetronGranisetron
• DolasetronDolasetron
• PalonosetronPalonosetron
Neurokinin-1 antagonistsNeurokinin-1 antagonists
• AprepitantAprepitant
Prokinetic agentsProkinetic agents
• MetoclopramideMetoclopramide
• DomperidoneDomperidone
• Macrolide antibiotics, Macrolide antibiotics, eg, erythromycineg, erythromycin
AntacidsAntacids
• AntacidsAntacids
• HH22 receptor antagonists receptor antagonistsCimetidineCimetidineFamotidineFamotidineRanitidineRanitidine
• Proton pump inhibitorsProton pump inhibitorsOmeprazoleOmeprazoleLansoprazoleLansoprazole
Other medicationsOther medications
• Dexamethasone 6 – 20 mg PO dailyDexamethasone 6 – 20 mg PO daily
• Tetrahydrocannabinol 2.5 – 5 mg PO tidTetrahydrocannabinol 2.5 – 5 mg PO tid
• Lorazepam 0.5 – 2 mg PO q 4 – 6 hLorazepam 0.5 – 2 mg PO q 4 – 6 h
• Octreotide 10 Octreotide 10 g / hr IV / SC infusiong / hr IV / SC infusion
or 100 or 100 g SC q 8 h for bowel obstructiong SC q 8 h for bowel obstruction
SummarySummary
Use comprehensive assessment and Use comprehensive assessment and
pathophysiology-based therapy pathophysiology-based therapy
to treat the cause and improve the to treat the cause and improve the
cancer experiencecancer experience